Abstract
Anthracycline chemotherapy is a widely-used and effective treatment for a wide spectrum of childhood cancers. Its use is limited by associated progressive and clinically significant cardiotoxic effects. Onset can be acute, early, or late. While acute onset is rare, long-term survivors have significantly elevated rates of cardiac morbidity and mortality. Major complications include cardiomyopathy, coronary artery disease, and atherosclerosis. Means of prevention and treatment continue to be explored including limiting cumulative anthracycline dose, controlling the rate of administration, and using liposomal preparations and novel anthracycline analogues. Dexrazoxane prior to anthracycline chemotherapy has been shown to significantly lower rates of elevated serum cardiac troponin levels, a marker of myocyte injury, indicating a cardioprotective effect. Pilot studies indicate that exercise interventions may also be beneficial in long-term survivors with cardiac damage. Support and study of this population to decrease the morbidity and morality associated with anthracycline-induced cardiotoxicity is indicated in a time sensitive fashion.
Similar content being viewed by others
References
Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., Smigal, C., & Thun, M. J. (2006). Cancer statistics, 2006. CA: A Cancer Journal for Clinicians, 56, 106–130.
Oeffinger, K. C., Mertens, A. C., Sklar, C. A., Kawashima, T., Hudson, M. M., Meadows, A. T., Friedman, D. L., Marina, N., Hobbie, W., Kadan-Lottick, N. S., Schwartz, C. L., Leisenring, W., & Robison, L. L. (2006). Chronic health conditions in adult survivors of childhood cancer. The New England Journal of Medicine, 355, 1572–1582.
Ries LA, Harkins D, Krapcho M, et al. (2006). SEER Cancer Statistics Review, 1975–2003, Bethesda, MD: National Cancer Institute.
Alvarez, J., Scully, R., Miller, T., Armstrong, F., Constine, L., Friedman, D., & Lipshultz, S. (2007). Long-term effects of treatments for childhood cancers. Current Opinion in Pediatrics, 19, 23–31.
Lipshultz, S. E., & Sallan, S. E. (1993). Cardiovascular abnormalities in long-term survivors of childhood malignancy. Journal of Clinical Oncology, 11, 1199–1203.
Adams, M., Duffy, S., Constine, L., & Lipshultz, S. (2005). Cardiovascular effects of cancer therapy. In C. Schwartz, W. Hobbie, L. Constine & K. Ruccione (Eds.) Survivors of choldhood and adolescent cancer (pp. 133–159). Berlin-Heidelberg: Springer-Verlag.
Arceci, R. J. (2006). Surviving childhood cancer: a special series on the successes and challenges after “cure”. Pediatric Blood & Cancer, 46, 119–121.
Bhatia, S., & Meadows, A. T. (2006). Long-term follow-up of childhood cancer survivors: future directions for clinical care and research. Pediatric Blood & Cancer, 46, 143–148.
Oeffinger, K. C., & Hudson, M. M. (2004). Long-term complications following childhood and adolescent cancer: foundations for providing risk-based health care for survivors. CA: A Cancer Journal for Clinicians, 54, 208–236.
Moller, T. R., Garwicz, S., Barlow, L., Falck Winther, J., Glattre, E., Olafsdottir, G., Olsen, J. H., Perfekt, R., Ritvanen, A., Sankila, R., & Tulinius, H. (2001). Decreasing late mortality among five-year survivors of cancer in childhood and adolescence: a population-based study in the Nordic countries. Journal of Clinical Oncology, 19, 3173–3181.
Mertens, A. C., Yasui, Y., Neglia, J. P., Potter, J. D., Nesbit, M. E. Jr., Ruccione, K., Smithson, W. A., & Robison, L. L. (2001). Late mortality experience in five-year survivors of childhood and adolescent cancer: the Childhood Cancer Survivor Study. Journal of Clinical Oncology, 19, 3163–3172.
Lipshultz, S. E., Lipsitz, S. R., Sallan, S. E., Dalton, V. M., Mone, S. M., Gelber, R. D., & Colan, S. D. (2005). Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. Journal of Clinical Oncology, 23, 2629–2636.
Lipshultz, S. E., Colan, S. D., Gelber, R. D., Perez-Atayde, A. R., Sallan, S. E., & Sanders, S. P. (1991). Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. The New England Journal of Medicine, 324, 808–815.
Gewirtz, D. A. (1999). A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochemical Pharmacology, 57, 727–741.
Doroshow, J. H., Locker, G. Y., & Myers, C. E. (1980). Enzymatic defenses of the mouse heart against reactive oxygen metabolites: alterations produced by doxorubicin. The Journal of clinical investigation, 65, 128–135.
Lebrecht, D., Setzer, B., Ketelsen, U. P., Haberstroh, J., & Walker, U. A. (2003). Time-dependent and tissue-specific accumulation of mtDNA and respiratory chain defects in chronic doxorubicin cardiomyopathy. Circulation, 108, 2423–2429.
Wallace, K. B. (2003). Doxorubicin-induced cardiac mitochondrionopathy. Pharmacology & Toxicology, 93, 105–115.
Minotti, G., Menna, P., Salvatorelli, E., Cairo, G., & Gianni, L. (2004). Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacological Reviews, 56, 185–229.
Berry, G. J., & Jorden, M. (2005). Pathology of radiation and anthracycline cardiotoxicity. Pediatric blood & cancer, 44, 630–637.
Adams, M. J., & Lipshultz, S. E. (2005). Pathophysiology of anthracycline- and radiation-associated cardiomyopathies: implications for screening and prevention. Pediatric Blood Cancer, 44, 600–606.
Giantris, A., Abdurrahman, L., Hinkle, A., Asselin, B., & Lipshultz, S. E. (1998). Anthracycline-induced cardiotoxicity in children and young adults. Critical Reviews in Oncology/Hematology, 27, 53–68.
Steinberg, J. S., Cohen, A. J., Wasserman, A. G., Cohen, P., & Ross, A. M. (1987). Acute arrhythmogenicity of doxorubicin administration. Cancer, 60, 1213–1218.
Frishman, W. H., Sung, H. M., Yee, H. C., Liu, L. L., Keefe, D., Einzig, A. I., & Dutcher, J. (1997). Cardiovascular toxicity with cancer chemotherapy. Current Problems in Cancer, 21, 301–360.
Swain, S. M., Whaley, F. S., & Ewer, M. S. (2003). Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer, 97, 2869–2879.
Steinherz, L. J., Steinherz, P. G., Tan, C. T., Heller, G., & Murphy, M. L. (1991). Cardiac toxicity 4 to 20 years after completing anthracycline therapy. Jama, 266, 1672–1677.
Lipshultz, S. E., Lipsitz, S. R., Mone, S. M., Goorin, A. M., Sallan, S. E., Sanders, S. P., Orav, E. J., Gelber, R. D., & Colan, S. D. (1995). Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. The New England Journal of Medicine, 332, 1738–1743.
Nysom, K., Holm, K., Lipsitz, S. R., Mone, S. M., Colan, S. D., Orav, E. J., Sallan, S. E., Olsen, J. H., Hertz, H., Jacobsen, J. R., & Lipshultz, S. E. (1998). Relationship between cumulative anthracycline dose and late cardiotoxicity in childhood acute lymphoblastic leukemia. Journal of Clinical Oncology, 16, 545–550.
Robert, J., Morvan, V. L., Smith, D., Pourquier, P., & Bonnet, J. (2005). Predicting drug response and toxicity based on gene polymorphisms. Critical Reviews in Oncology/Hematology, 54, 171–96.
Lipshultz, S. E., Lipsitz, S. R., Hinkle, A. S., Constine, L. S., French, C. A., Rovitelli, A. M. K., Proukou, C., Lopez-Mitnik, G., Adams, M. J., Hale, R., Rifai, N., & Miller, T. L. (2005). Cardiovascular status, subsequent risk, and associated factors in long-term survivors of childhood cancer in a population-based NCI study. Circulation 112, II-476 (#2292).
Bhatia, R. S., Tu, J. V., Lee, D. S., Austin, P. C., Fang, J., Haouzi, A., Gong, Y., & Liu, P. P. (2006). Outcome of heart failure with preserved ejection fraction in a population-based study. The New England Journal of Medicine, 355, 260–9.
Owan, T. E., Hodge, D. O., Herges, R. M., Jacobsen, S. J., Roger, V. L., & Redfield, M. M. (2006). Trends in prevalence and outcome of heart failure with preserved ejection fraction. The New England Journal of Medicine, 355, 251–9.
Wouters, K. A., Kremer, L. C. M., Miller, T. L., Herman, E. H., & Lipshultz, S. E. (2005). Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies. British Journal of Haematology, 131, 561–78.
van Dalen, E. C., Caron, H. N., Dickinson, H. O. & Kremer, L. C. (2005). Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev, CD003917.
Lipshultz, S. E., Giantris, A. L., Lipsitz, S. R., Kimball Dalton, V., Asselin, B. L., Barr, R. D., Clavell, L. A., Hurwitz, C. A., Moghrabi, A., Samson, Y., Schorin, M. A., Gelber, R. D., Sallan, S. E., & Colan, S. D. (2002). Doxorubicin administration by continuous infusion is not cardioprotective: the Dana-Farber 91–01 Acute Lymphoblastic Leukemia protocol. Journal of Clinical Oncology, 20, 1677–82.
Ewer, M. S., Martin, F. J., Henderson, C., Shapiro, C. L., Benjamin, R. S., & Gabizon, A. A. (2004). Cardiac safety of liposomal anthracyclines. Seminars in Oncology, 31, 161–81.
Theodoulou, M., & Hudis, C. (2004). Cardiac profiles of liposomal anthracyclines: greater cardiac safety versus conventional doxorubicin? Cancer, 100, 2052–63.
Lahtinen, R., Kuikka, J., Nousiainen, T., Uusitupa, M., & Lansimies, E. (1991). Cardiotoxicity of epirubicin and doxorubicin: A double-blind randomized study. European Journal of Haematology, 46, 301–5.
Meinardi, M. T., van Veldhuisen, D. J., Gietema, J. A., Dolsma, W. V., Boomsma, F., van den Berg, M. P., Volkers, C., Haaksma, J., de Vries, E. G., Sleijfer, D. T., & van der Graaf, W. T. (2001). Prospective evaluation of early cardiac damage induced by epirubicin-containing adjuvant chemotherapy and locoregional radiotherapy in breast cancer patients. Journal of Clinical Oncology, 19, 2746–53.
Robert, J., Rigal-Huguet, F., & Hurteloup, P. (1992). Comparative pharmacokinetic study of idarubicin and daunorubicin in leukemia patients. Hematological Oncology, 10, 111–6.
Martoni, A., Piana, E., Guaraldi, M., Cilenti, G., Farris, A., Saccani, F., Becchi, G., & Pannuti, F. (1990). Comparative phase II study of idarubicin versus doxorubicin in advanced breast cancer. Oncology, 47, 427–32.
Anderlini, P., Benjamin, R. S., Wong, F. C., Kantarjian, H. M., Andreeff, M., Kornblau, S. M., O’Brien, S., Mackay, B., Ewer, M. S., Pierce, S. A., et al. (1995). Idarubicin cardiotoxicity: a retrospective study in acute myeloid leukemia and myelodysplasia. Journal of Clinical Oncology, 13, 2827–34.
Neidhart, J. A., Gochnour, D., Roach, R., Hoth, D., & Young, D. (1986). A comparison of mitoxantrone and doxorubicin in breast cancer. Journal of Clinical Oncology, 4, 672–7.
Cowan, J. D., Neidhart, J., McClure, S., Coltman, C. A. Jr., Gumbart, C., Martino, S., Hutchins, L. F., Stephens, R. L., Vaughan, C. B., & Osborne, C. K. (1991). Randomized trial of doxorubicin, bisantrene, and mitoxantrone in advanced breast cancer: A Southwest Oncology Group study. Journal of the National Cancer Institute, 83, 1077–84.
Herman, E. H., Zhang, J., Rifai, N., Lipshultz, S. E., Hasinoff, B. B., Chadwick, D. P., Knapton, A., Chai, J., & Ferrans, V. J. (2001). The use of serum levels of cardiac troponin T to compare the protective activity of dexrazoxane against doxorubicin- and mitoxantrone-induced cardiotoxicity. Cancer Chemotheraphy Pharmacology, 48, 297–304.
Lipshultz, S. E., Rifai, N., Dalton, V. M., Levy, D. E., Silverman, L. B., Lipsitz, S. R., Colan, S. D., Asselin, B. L., Barr, R. D., Clavell, L. A., Hurwitz, C. A., Moghrabi, A., Samson, Y., Schorin, M. A., Gelber, R. D., & Sallan, S. E. (2004). The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. The New England Journal of Medicine, 351, 145–153.
Sallan, S. E., & Lipshultz, S. E. (2005). Wise up: Do not do it without protection! Pediatric Blood & Cancer, 45, 872–873.
The SOLVD Investigators. (1991). Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The New England Journal of Medicine, 325, 293–302.
The SOLVD Investigators. (1992). Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The New England Journal of Medicine, 327, 685–691.
Lipshultz, S. E., Lipsitz, S. R., Sallan, S. E., Simbre, V. C. 2nd, Shaikh, S. L., Mone, S. M., Gelber, R. D., & Colan, S. D. (2002). Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer. Journal of Clinical Oncology, 20, 4517–4522.
Lipshultz, S. E., & Colan, S. D. (2004). Cardiovascular trials in long-term survivors of childhood cancer. Journal of Clinical Oncology, 22, 769–773.
Cardinale, D., Colombo, A., Sandri, M. T., Lamantia, G., Colombo, N., Civelli, M., Martinelli, G., Veglia, F., Fiorentini, C., & Cipolla, C. M. (2006). Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation, 114, 2474–2481.
Lipshultz, S. E., Vlach, S. A., Lipsitz, S. R., Sallan, S. E., Schwartz, M. L., & Colan, S. D. (2005). Cardiac changes associated with growth hormone therapy among children treated with anthracyclines. Pediatrics, 115, 1613–1622.
Cheitlin, M. D., Armstrong, W. F., Aurigemma, G. P., Beller, G. A., Bierman, F. Z., Davis, J. L., Douglas, P. S., Faxon, D. P., Gillam, L. D., Kimball, T. R., Kussmaul, W. G., Pearlman, A. S., Philbrick, J. T., Rakowski, H., Thys, D. M., Antman, E. M., Smith, S. C. Jr., Alpert, J. S., Gregoratos, G., Anderson, J. L., Hiratzka, L. F., Hunt, S. A., Fuster, V., Jacobs, A. K., Gibbons, R. J., & Russell, R. O. (2003). ACC/AHA/ASE 2003 guideline update for the clinical application of echocardiography: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography). Circulation, 108, 1146–1162.
Fried, I., Bar-Oz, B., Perles, Z., Rein, A. J., Zonis, Z., & Nir, A. (2006). N-terminal pro-B-type natriuretic peptide levels in acute versus chronic left ventricular dysfunction. The Journal of Pediatrics, 149, 28–31.
Bibbins-Domingo, K., Gupta, R., Na, B., Wu, A. H., Schiller, N. B., & Whooley, M. A. (2007). N-terminal fragment of the prohormone brain-type natriuretic peptide (NT-proBNP), cardiovascular events, and mortality in patients with stable coronary heart disease. Jama, 297, 169–176.
Miller, T. L., Horgan, S., & Lipshultz, S. E. (2005). Exercise rehabilitation of pediatric patients with cardiovascular disease. Progress in Pediatric Cardiology, 20, 27–37.
Hinkle, A. S., Proukou, C., French, C. A., Kozlowski, A. M., Constine, L. S., Lipsitz, S. R., Miller, T. L., & Lipshultz, S. E. (2004). A clinic-based, comprehensive care model for studying late effects in long-term survivors of pediatric illnesses. Pediatrics, 113, 1141–1145.
Grenier, M. A., & Lipshultz, S. E. (1998). Epidemiology of anthracycline cardiotoxicity in children and adults. Seminars in Oncology, 25, 72–85.
Acknowledgments
This paper has been supported in part by grants from the National Cancer Institute (CA68484-SL, CA34183-SL, CA79060-SL, CA06516-SL), National Heart, Lung, and Blood Institute (HL69800-SL, HL53392-SL, HL59837-SL, HL53392-SL), the Lance Armstrong Foundation (SL), and the Children’s Cardiomyopathy Foundation (SL).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Scully, R.E., Lipshultz, S.E. Anthracycline cardiotoxicity in long-term survivors of childhood cancer. Cardiovasc Toxicol 7, 122–128 (2007). https://doi.org/10.1007/s12012-007-0006-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12012-007-0006-4